Pregabalin

ApprovedCompleted

0 views this week 0 watching⚡ Active

Interest: 43/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Painful Diabetic Neuropathy and Post Herpetic Neuralgia

Conditions

Painful Diabetic Neuropathy and Post Herpetic Neuralgia

Trial Timeline

Nov 1, 2004 → Feb 1, 2006

NCT ID

NCT00629681

About Pregabalin

Pregabalin is a approved stage product being developed by Pfizer for Painful Diabetic Neuropathy and Post Herpetic Neuralgia. The current trial status is completed. This product is registered under clinical trial identifier NCT00629681. Target conditions include Painful Diabetic Neuropathy and Post Herpetic Neuralgia.

What happened to similar drugs?

6 of 20 similar drugs in Painful Diabetic Neuropathy and Post Herpetic Neuralgia were approved

Approved (6) Terminated (2) Active (12)

✅Popliteal nerve block including liposomal bupivacaine + Adductor canal nerve block including liposomal bupivacaine + Continuous popliteal nerve block with normal saline + Popliteal nerve block with exclusively unencapsulated bupivacaine + Adductor canal nerve block with exclusively unencapsulated bupivacaine + Continuous popliteal nerve block with unencapsulated bupivacainePacira BiosciencesApproved

✅Qutenza + PregabalinAstellas PharmaApproved

✅duloxetine hydrochlorideEli LillyApproved

✅duloxetine hydrochloride + pregabalin + gabapentinEli LillyApproved

✅pregabalinPfizerApproved

✅PregabalinPfizerApproved

🔄QUTENZAAstellas PharmaPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01773993	Pre-clinical	Completed	Feb 1, 2013	Jul 1, 2017	Pain Associated With Fibromyalgia
NCT01603394	Approved	Terminated	Oct 1, 2012	Jun 1, 2013	Postherpetic Neuralgia
NCT01463306	Phase 3	Completed	Feb 21, 2012	Aug 22, 2019	Epilepsy, Partial Seizures
NCT01298466	Approved	Withdrawn	Feb 1, 2012	Feb 1, 2013	Low Back Pain
NCT01474772	Phase 3	Completed	Oct 1, 2011	Jul 1, 2013	Diabetic Peripheral Neuropathy
NCT01397006	Approved	Withdrawn	Sep 1, 2011	Mar 1, 2014	Fibromyalgia
NCT01020526	Approved	Completed	Sep 1, 2010	Jun 1, 2015	Fibromyalgia
NCT01202227	Phase 3	Completed	Sep 1, 2010	Mar 1, 2012	Spinal Cord Diseases
NCT01226667	Approved	Completed	Jul 1, 2010	Jul 1, 2012	Fibromyalgia
NCT00819988	Phase 3	Completed	May 1, 2009	Oct 1, 2011	Delirium
NCT00596466	Phase 3	Completed	Apr 1, 2008	Dec 1, 2011	Epilepsy
NCT00553280	Phase 3	Completed	Feb 1, 2008	Jan 1, 2010	Diabetic Neuropathy, Painful
NCT01061697	Approved	Completed	Jan 1, 2008	Apr 1, 2010	Cervical Spondylosis
NCT00891397	Pre-clinical	Terminated	Nov 1, 2007	Oct 1, 2010	Complex Regional Pain Syndromes
NCT00448916	Phase 3	Completed	May 1, 2007	Oct 1, 2013	Epilepsies, Partial
NCT00407797	Approved	Terminated	Mar 1, 2007	Aug 1, 2009	Partial Seizures
NCT00424372	Phase 3	Completed	Jan 12, 2007	Aug 19, 2008	Neuralgia, Postherpetic
NCT00407511	Approved	Completed	Jan 1, 2007	Jul 1, 2008	Diabetic Peripheral Neuropathic Pain (DPN)
NCT00346034	Phase 3	Completed	Dec 1, 2006	Feb 1, 2008	Fibromyalgia
NCT00843284	Pre-clinical	Completed	Sep 1, 2006	Mar 1, 2008	Neuropathic Pain

Competing Products

20 competing products in Painful Diabetic Neuropathy and Post Herpetic Neuralgia

See all competitors

Product	Company	Stage	Hype Score
Popliteal nerve block including liposomal bupivacaine + Adductor canal nerve block including liposomal bupivacaine + Continuous popliteal nerve block with normal saline + Popliteal nerve block with exclusively unencapsulated bupivacaine + Adductor canal nerve block with exclusively unencapsulated bupivacaine + Continuous popliteal nerve block with unencapsulated bupivacaine	Pacira Biosciences	Approved	44
ASP3662 + pregabalin + ASP3662 placebo + pregabalin placebo	Astellas Pharma	Phase 2	27
QUTENZA	Astellas Pharma	Phase 3	40
Qutenza + Pregabalin	Astellas Pharma	Approved	43
duloxetine hydrochloride	Eli Lilly	Approved	43
Duloxetine hydrochloride + placebo	Eli Lilly	Phase 3	40
Duloxetine + Placebo	Eli Lilly	Phase 3	40
duloxetine hydrochloride + pregabalin + gabapentin	Eli Lilly	Approved	43
Duloxetine + Pregabalin + Placebo	Eli Lilly	Phase 3	40
Placebo + Pregabalin + LY545694 21 mg + LY545694 49 mg + LY545694 105 mg	Eli Lilly	Phase 2	35
GRC 17356 + Matching Placebo	Glenmark Pharmaceuticals	Phase 2	35
GRC 17536 (Medium Dose) + GRC 17536 (Low Dose) + Placebo	Glenmark Pharmaceuticals	Phase 2	27
Tapentadol extended release (ER) + Oxycodone controlled release (CR)	Johnson & Johnson	Phase 3	32
AZD5213 + pregabalin + Placebo + pregabalin capsules	AstraZeneca	Phase 2	35
MEDI7352	AstraZeneca	Phase 2	27
MEDI7352	AstraZeneca	Phase 2	35
MEDI7352 + Placebo	AstraZeneca	Phase 1	29
MK-6096 + Placebo	Merck	Phase 2	35
Comparator: A: Pregabalin + Comparator: B: Duloxetine + Comparator: C: Diphenhydramine hydrochloride	Merck	Phase 2	27
EMA401 + Placebo	Novartis	Phase 2	27